Jeffrey Hager

Dr. Hager currently serves as Chief Scientific Officer of Coho Therapeutics, a company focused on small molecule, molecular glues to target oncoproteins for degradation. He is also a current member of the Scientific Advisory Boards of IDEAYA Biosciences, Olema Oncology, and TYRA Biosciences, Blacksmith Medicines and an Executive in Residence at Boxer Capital.

Between 2015 – 2019, Dr. Hager held multiple positions at IDEAYA including Senior Vice President and Chief Technology Officer and Head of Target Discovery and External Innovation at IDEAYA and Senior Vice President and Head of Biology. Prior to IDEAYA, Dr. Hager was VP of Biology at Seragon Pharmaceuticals (acquired by Roche/Genentech) where he oversaw all in vitro and in vivo biology and pharmacology that lead to the discovery of two novel, clinical-stage selective estrogen receptor degraders (SERDs) developed as treatment for hormone receptor positive breast cancer. From 2009 – 2013, Dr. Hager was Senior Director at Aragon Pharmaceuticals, which was acquired by Johnson & Johnson. At Aragon, his team was central in pre-clinical development of the novel anti-androgen apalutamide (Erleada™), an FDA approved treatment for early-stage castration resistant prostate cancer. Before his work at Aragon, Dr. Hager was Associate Director of Biology at Apoptos, Inc. and, before that, a Principal Scientist and Head of Cancer Pharmacology at Kalypsys, Inc.

Dr. Hager received a Ph.D. in molecular and cell biology from the University of California, Berkeley. He was a postdoctoral fellow and staff scientist at the University of California, San Francisco and is an author of publications in Annual Review of Cancer Biology, eLife, Science, Nature Genetics, Cancer Cell, Cancer Research and Cancer Discovery.